The table below details the percent susceptibility of inpatient isolates of Pseudomonas aeruginosa to single agents and to the combination of antimicrobials indicated (number to the right of the arrow). Excludes isolates from patients with cystic fibrosis. Data are from 2019-2021.
MER=meropenem; TOB=tobramycin; PIPTAZ=piperacillin/tazobactam; CFPM=cefepime; CIP=ciprofloxacin
| Population |
Number of Isolates |
PIPTAZ --> PIPTAZ + CIP |
PIPTAZ --> PIPTAZ + TOB |
CFPM --> CFPM + CIP |
CFPM --> CFPM + TOB |
MER --> MER + CIP |
MER --> MER + TOB |
|
All inpatient/ED isolates |
115 |
87%--> 97% |
87% --> 100% |
90% --> 96% |
90% --> 99% |
91% --> 96% |
91% --> 96% |
|
ICU* |
53 |
87% --> 98% |
87% --> 100% |
89% --> 94% |
89% --> 98% |
87% --> 94% |
87% --> 98% |
|
non-ICU |
62 |
87% --> 95% |
87% --> 100% |
90% --> 97% |
90% --> 100% |
95% --> 97% |
95% --> 100% |
* ICU = combined ICN, PICU and CICU - 5 isolates from ICN, remainder from PICU, PCICU